阿克提斯肿瘤
AKTS
15.06
-0.95
-5.93%
阿克提斯肿瘤
US · AKTS
#3249 按市值排名
上市于 2026
15.06
-0.95
-5.93%
实时 - 追踪5344个代码 - 心跳于512秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了3家。
- 机构持股总比例下降了0.5个百分点。
机构持股
- 机构持股比例
- 89.77% -0.50pp
- 机构数量
- 144 +3
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund30.83%
Hedge Fund23.51%
Mutual Fund23.03%
Public Company11.98%
Individual/Insider0.46%
Family Office/Trust0.20%
Private Company0.11%
Other9.77%
主要股东 截至 2026-01-12
Eli Lilly and Company
11.41% · 6.34M 股
EcoR1 Capital, LLC
10.56% · 5.88M 股
Vida Ventures Advisors, LLC
10.48% · 5.83M 股
MPM BioImpact LLC
8.69% · 4.84M 股
CHI Advisors LLC
5.52% · 3.07M 股
T. Rowe Price Group, Inc.
5.06% · 2.81M 股
Blue Owl Credit Private Fund Advisors LLC
4.37% · 2.43M 股
BlackRock
4.10% · 2.28M 股
Wellington Management Group
3.54% · 1.97M 股
RTW Investments, LP
2.86% · 1.59M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪32份申报 · 7次买入 · 5次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Eli Lilly and Company | -- | 11.41% |
| EcoR1 Capital, LLC | -- | 10.56% |
| Vida Ventures Advisors, LLC | -- | 10.48% |
| Paul Feldman | Chief Scientific Officer | 0.26% |
| Matthew Roden | Chief Executive Officer | 0.17% |
| Lloyd Segal | Independent Director | 0.04% |
| MPM BioImpact LLC | -- | -- |
| Todd Foley | Chairperson | -- |
| Helen Kim | Independent Director | -- |
| Michael Sherman | Independent Director | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-22 | Akos Czibere | Chief Medical Officer | Derivative Exercise and Sale | -12,500 | $4.95–21.03 |
| 2026-07-19 | Ken Herrmann | Chair of Scientific Advisory Board & Independent Director | Derivative Exercise and Sale | -4,856 | $0.08–24.56 |
| 2026-07-16 | Ken Herrmann | Chair of Scientific Advisory Board & Independent Director | Derivative Exercise and Sale | -3,065 | $0.08–25.21 |
| 2026-07-07 | Shulamit Ron-Bigger | Chief Operating Officer | Derivative Exercise and Sale | -50,000 | $3.66–28.75 |
| 2026-07-07 | Akos Czibere | Chief Medical Officer | Derivative Exercise and Sale | -50,000 | $4.95–28.71 |
| 2026-01-11 | MPM BioImpact LLC | -- | Private Acquisition | +1,112,777 | $18.00 |
| 2026-01-11 | MPM BioImpact LLC | -- | Derivative Exercise and Retained | +8,208,187 | -- |
| 2026-01-11 | Eli Lilly and Company | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-01-11 | Lloyd Segal | Independent Director | Derivative Exercise and Retained | +19,631 | -- |
| 2026-01-11 | EcoR1 Capital, LLC | -- | Private Acquisition | +2,222,222 | $18.00 |
| 2026-01-11 | EcoR1 Capital, LLC | -- | Derivative Exercise and Retained | +2,602,247 | -- |
| 2026-01-11 | Vida Ventures Advisors, LLC | -- | Private Acquisition | +835,000 | $18.00 |
| 2026-01-11 | Vida Ventures Advisors, LLC | -- | Derivative Exercise and Retained | +4,994,212 | -- |
| 2026-01-07 | MPM BioImpact LLC | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-01-07 | Todd Foley | Chairperson | Initial Statement of Beneficial | 0 | -- |
| 2026-01-07 | Helen Kim | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-01-07 | Michael Sherman | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-01-07 | Lloyd Segal | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-01-07 | Mary Thistle | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-01-07 | Matthew Roden | Chief Executive Officer | Initial Statement of Beneficial | 0 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:25 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
阿克提斯肿瘤 讨论区 0 条评论